Dublin, Aug. 30, 2023 (GLOBE NEWSWIRE) -- The "Minimal Residual Disease Testing: Global Markets and Technologies" report has been added to ResearchAndMarkets.com's offering.
The global market for minimal residual disease (MRD) testing is set to witness a transformative phase, as projected by a comprehensive report that examines market trends from 2022 as the base year and forecasts through 2028 with a compounded annual growth rate (CAGR) projection.
This report meticulously analyzes both leading and emerging technologies, applications, end-users, and product pipelines within the domain of minimal residual disease testing. It offers detailed profiles of key market players, outlining their specific products, financial data, and recent market activities.
In the realm of cancer treatment, the past decade has witnessed a remarkable shift due to the advent of efficient medications and accessible immunotherapy like targeted antibodies and adoptive cell therapy. A pivotal tool in this landscape is minimal residual disease (MRD) testing, which has found its place in clinical trials as a valuable asset for dynamic risk-adapted treatments.
MRD testing has already proven its utility in a range of clinical trials, serving as a predictive marker, an efficacy assessment tool, a comparative method for various treatment modalities, and even as a basis for adaptive therapeutic approaches, especially in maintenance periods and early salvage scenarios.
The value of MRD testing becomes particularly evident as it empowers doctors to make informed decisions by providing a comprehensive understanding of a patient's response to therapy. Supported by a growing body of clinical evidence and real-world data, MRD has emerged as a critical marker for patient outcomes in blood malignancies, especially with the advent of newer and more potent medications.
Moreover, investments in MRD testing programs are anticipated to be a driving force behind market expansion. A surge in research activities in MRD diagnostics and monitoring further bolsters market demand. Notably, GRAIL's collaboration with leading healthcare companies in January 2021 exemplifies the drive for MRD identification through innovative methodologies.
The report also delves into the dynamics of mergers, acquisitions, and funding activities and their impact on the competitive landscape. It provides a comprehensive breakdown of the MRD testing market based on technology, application, and end user, segmenting the market into polymerase chain reaction (PCR), next-generation sequencing (NGS), flow cytometry, and other technologies.
Report Includes
- Analyses of the global market trends, historical market revenue (sales figures) data from 2021-2022, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2028
- Estimation of the actual market size and revenue forecast for global minimal residual disease testing market in USD million values, and corresponding market share analysis based on technology, application, and region
- In-depth information (facts and figures) concerning the market growth drivers, opportunities and challenges, prospects, technologies, regulatory scenarios, and the impact of COVID-19 on the progress of this market
- Detailed description of specific somatic or germline mutations that serve as precise markers to diagnose cancer during ongoing investigations
- Coverage of major cancers such as leukemia, lymphoma, and multiple myeloma, and discussion on how MRD level monitoring enables more precise evaluations, thereby identifying the amount of risk or enabling early prevention of future relapse
- Discussion of the importance of ESG in global minimal residual disease testing market, consumer attitudes, risks and opportunity assessment, future trends, and ESG followed practices within the industry
- A look at the major vendors in minimal residual disease testing market, and analyze the structure of this industry with respect to company market shares, venture fundings, and recent merger and acquisition (M&A) activities
- Identification of the major stakeholders and analysis of their company competitive landscape based on recent developments, key financials and segmental revenues, and operational integration
- Detailed company profiles of the leading market players, including Adaptive Biotechnologies, Invitae Corp., Guardant Health, Natera Inc., NeoGenomics Inc., Exact Sciences Corp., and Quest Diagnostics
Company Profiles
- Adaptive Biotechnologies Corp.
- Amgen Inc.
- Astrazeneca plc
- Bio-Rad Laboratories Inc.
- Cergentis B.V.
- Exact Sciences Corp.
- Guardant Health Inc.
- Illumina Inc. (Grail LLC)
- Invitae
- Invivoscribe Inc.
- Natera Inc.
- Neogenomics Inc.
- Qiagen
- Sysmex Corp.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 152 |
| Forecast Period | 2023 - 2028 |
| Estimated Market Value (USD) in 2023 | $2.2 Billion |
| Forecasted Market Value (USD) by 2028 | $4.3 Billion |
| Compound Annual Growth Rate | 14.3% |
| Regions Covered | Global |
Key Topics Covered:
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing this Study
- Scope of Report
- Research Methodology
- Information Sources
- Geographic Breakdown
Chapter 2 Summary and Highlights
- Market Outlook
Chapter 3 Market Overview
- Definition of Minimal Residual Disease
- Importance of Detecting Minimal Residual Disease
- Indications for Minimal Residual Disease Testing
- Techniques Used for Detecting Minimal Residual Disease
Chapter 4 Market Dynamics
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact of Covid-19 on Minimal Residual Disease Testing Market
- Regulatory Landscape
- Clinical Laboratory Improvement Amendments of 1988 (Clia)
- State Licensing Laws
- The U.S. Food and Drug Administration
Chapter 5 Global Minimal Residual Disease Testing Market by Technology
- Overview
- Flow Cytometry
- Polymerase Chain Reaction (Pcr)
- Next-Generation Sequencing (Ngs)
- Others
Chapter 6 Global Minimal Residual Disease Testing Market by Application
- Overview
- Hematological Malignancies
- Leukemia
- Lymphoma
- Myeloma
- Solid Tumors
- Others
Chapter 7 Global Minimal Residual Disease Testing Market by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 8 Esg Developments
- Importance of Esg in Minimal Residual Disease Testing Industry
- Esg Ratings and Metrics: Understanding the Data
- Esg Practices in the Minimal Residual Disease Testing Industry
- Environmental Performance
- Social Performance
- Governance Performance
- Future Trends
- Research Viewpoint
Chapter 9 Emerging Technologies and Developments
- Emerging Technologies
- Digital Polymerase Chain Reaction (Dpcr)
Chapter 10 M&A Analysis
- M&A Analysis
Chapter 11 Competitive Intelligence
- Top Market Players Ranking, 2022
- Key Strategies Adopted by Companies
- Collaborations
- Marketing Activity
- New Product Launch
- Expansion
- Acquisition
- Partnerships, Agreements and Alliances
- Clinical Data Studies
- Others
For more information about this report visit https://www.researchandmarkets.com/r/hgo796
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
